降低女性原发性乳腺癌风险的药物使用:美国预防服务工作组更新版证据报告与系统综述
在安慰剂对照试验中,他莫昔芬(RR 0.69,95%CI 0.59-0.84;4项试验,n=28421)、雷洛昔芬(RR 0.44,95%CI 0.24-0.80;2项试验,n=17806)和芳香化酶抑制剂依西美坦及阿那曲唑(RR 0.45,95%CI 0.26-0.70;2项试验,n=8424)与浸润性乳腺癌发病率降低相关。乳腺癌风险评估方法的判别准确性较低(AUC 0.55-0.65)。
要点
- 他莫昔芬、雷洛昔芬和芳香化酶抑制剂与女性原发性浸润性乳腺癌风险降低相关。
- 在1项长期随访试验中,雷洛昔芬的浸润性乳腺癌风险高于他莫昔芬(RR 1.24,95%CI 1.05-1.47;n=19747)。
- 乳腺癌风险评估方法在预测个体乳腺癌概率方面准确性低(AUC 0.55-0.65)。
核心结论
- 他莫昔芬、雷洛昔芬和芳香化酶抑制剂与女性原发性浸润性乳腺癌风险降低相关,但也伴随不良反应,且不良反应因药物而异。
- 用于识别乳腺癌风险增加患者的风险分层方法准确性低。
研究设计与样本
- 本系统综述检索了Cochrane对照试验中心注册库和系统综述数据库、EMBASE和MEDLINE(2013年1月1日至2019年2月1日),并手工审查参考文献列表。
- 纳入乳腺癌风险评估方法的判别准确性研究、他莫昔芬、雷洛昔芬和芳香化酶抑制剂用于原发性乳腺癌预防的随机临床试验以及药物不良反应研究。
主要发现
- 25项研究中的18种风险评估方法在预测个体乳腺癌概率方面准确性低(AUC 0.55-0.65)。
- 在安慰剂对照试验中,他莫昔芬(RR 0.69,95%CI 0.59-0.84;4项试验,n=28421)、雷洛昔芬(RR 0.44,95%CI 0.24-0.80;2项试验,n=17806)和芳香化酶抑制剂依西美坦及阿那曲唑(RR 0.45,95%CI 0.26-0.70;2项试验,n=8424)与浸润性乳腺癌发病率降低相关。
- 在1项长期随访试验中,雷洛昔芬的浸润性乳腺癌风险高于他莫昔芬(RR 1.24,95%CI 1.05-1.47;n=19747)。
- 与安慰剂相比,雷洛昔芬与椎体骨折风险降低相关(RR 0.61,95%CI 0.53-0.73;2项试验,n=16929),他莫昔芬与非椎体骨折风险降低相关(RR 0.66,95%CI 0.45-0.98;1项试验,n=13388)。
- 与安慰剂相比,他莫昔芬和雷洛昔芬与血栓栓塞事件增加相关,且他莫昔芬的事件数多于雷洛昔芬;与安慰剂相比,他莫昔芬与子宫内膜癌和白内障风险升高相关;症状性效应(如血管舒缩、肌肉骨骼)因药物而异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Medications to reduce risk of breast cancer are effective for women at increased risk but also cause adverse effects. OBJECTIVE: To update the 2013 US Preventive Services Task Force systematic review on medications to reduce risk of primary (first diagnosis) invasive breast cancer in women. DATA SOURCES: Cochrane Central Register of Controlled Trials and Database of Systematic Reviews, EMBASE, and MEDLINE (January 1, 2013, to February 1, 2019); manual review of reference lists. STUDY SELECTION: Discriminatory accuracy studies of breast cancer risk assessment methods; randomized clinical trials of tamoxifen, raloxifene, and aromatase inhibitors for primary breast cancer prevention; studies of medication adverse effects. DATA EXTRACTION AND SYNTHESIS: Investigators abstracted data on methods, participant characteristics, eligibility criteria, outcome ascertainment, and follow-up. Results of individual trials were combined by using a profile likelihood random-effects model. MAIN OUTCOMES AND MEASURES: Probability of breast cancer in individuals (area under the receiver operating characteristic curve [AUC]); incidence of breast cancer, fractures, thromboembolic events, coronary heart disease events, stroke, endometrial cancer, and cataracts; and mortality. RESULTS: A total of 46 studies (82 articles [>5 million participants]) were included. Eighteen risk assessment methods in 25 studies reported low accuracy in predicting the probability of breast cancer in individuals (AUC, 0.55-0.65). In placebo-controlled trials, tamoxifen (risk ratio [RR], 0.69 [95% CI, 0.59-0.84]; 4 trials [n = 28 421]), raloxifene (RR, 0.44 [95% CI, 0.24-0.80]; 2 trials [n = 17 806]), and the aromatase inhibitors exemestane and anastrozole (RR, 0.45 [95% CI, 0.26-0.70]; 2 trials [n = 8424]) were associated with a lower incidence of invasive breast cancer. Risk for invasive breast cancer was higher for raloxifene than tamoxifen in 1 trial after long-term follow-up (RR, 1.24 [95% CI, 1.05-1.47]; n = 19 747). Raloxifene was associated with lower risk for vertebral fractures (RR, 0.61 [95% CI, 0.53-0.73]; 2 trials [n = 16 929]) and tamoxifen was associated with lower risk for nonvertebral fractures (RR, 0.66 [95% CI, 0.45-0.98]; 1 trial [n = 13 388]) compared with placebo. Tamoxifen and raloxifene were associated with increased thromboembolic events compared with placebo; tamoxifen was associated with more events than raloxifene. Tamoxifen was associated with higher risk of endometrial cancer and cataracts compared with placebo. Symptomatic effects (eg, vasomotor, musculoskeletal) varied by medication. CONCLUSIONS AND RELEVANCE: Tamoxifen, raloxifene, and aromatase inhibitors were associated with lower risk of primary invasive breast cancer in women but also were associated with adverse effects that differed between medications. Risk stratification methods to identify patients with increased breast cancer risk demonstrated low accuracy.
引用
- Nelson HD, Fu R, Zakher B, et al. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2019. PMID: 31479143. doi:10.1001/jama.2019.5780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。